The therapeutic effect of proton pump inhibitors on Helicobacter pylori-positive gastric ulcers. 1999

M Sasakii, and T Joh, and Y Yokoyama, and K Seno, and K Tsuchida, and T Kurokawa, and M Itoh
Department of Internal Medicine, Nagoya City University Medical School, Aichi, Japan.

The aim of the present study was to elucidate the risk factors that could delay gastric ulcer healing when either a proton pump inhibitor or an H2-receptor antagonist is used for gastric ulcer treatment. Endoscopically-diagnosed gastric ulcer patients (216 men and 96 women, mean age: 57+/-13 years) were investigated. All patients were consecutively recruited and randomly assigned to receive H2-receptor antagonist (n = 196) or proton pump inhibitor (n = 116) treatment for eight weeks. Chi-squared tests and multivariate analysis to determine factors influencing ulcer healing were used to analyse the patients profiles, endoscopic findings, and Helicobacter pylori-infection status. In the H2-receptor antagonist group, the most important risk factor was a large ulcer size (> 2 cm diam.), followed by a linear shape of the ulcer, undermining tendency of ulcer, previous history of gastric ulcer, and H. pylori infection. In the proton pump inhibitor group, linear shape of the ulcer was the only significant risk factor for slow ulcer healing; other factors, including H. pylori infection, were insignificant. These results indicate that ulcer morphology may be the most important information for predicting ulcer healing, and that H. pylori infection does not delay gastric ulcer healing when proton pump inhibitor treatment is used.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009853 Omeprazole A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. H 168-68,Omeprazole Magnesium,Omeprazole Sodium,Prilosec,H 168 68,H 16868,Magnesium, Omeprazole,Sodium, Omeprazole
D010352 Patient Dropouts Discontinuance of care received by patient(s) due to reasons other than full recovery from the disease. Dropout, Patient,Dropouts, Patient,Patient Dropout
D011899 Ranitidine A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers. AH-19065,Biotidin,N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine,Ranisen,Ranitidin,Ranitidine Hydrochloride,Sostril,Zantac,Zantic,AH 19065,AH19065,Hydrochloride, Ranitidine
D005260 Female Females
D006635 Histamine H2 Antagonists Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. Antihistaminics, H2,H2 Receptor Blockader,Histamine H2 Antagonist,Histamine H2 Blocker,Histamine H2 Receptor Antagonist,Histamine H2 Receptor Antagonists,Histamine H2 Receptor Blockader,Histamine H2 Receptor Blockaders,Antagonists, Histamine H2,Blockaders, Histamine H2 Receptor,H2 Receptor Blockaders,Histamine H2 Blockers,Receptor Antagonists, Histamine H2,Receptor Blockaders, H2,Antagonist, Histamine H2,Blockader, H2 Receptor,Blockaders, H2 Receptor,Blocker, Histamine H2,Blockers, Histamine H2,H2 Antagonist, Histamine,H2 Antagonists, Histamine,H2 Antihistaminics,H2 Blocker, Histamine,H2 Blockers, Histamine,Receptor Blockader, H2
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

M Sasakii, and T Joh, and Y Yokoyama, and K Seno, and K Tsuchida, and T Kurokawa, and M Itoh
June 1996, Alimentary pharmacology & therapeutics,
M Sasakii, and T Joh, and Y Yokoyama, and K Seno, and K Tsuchida, and T Kurokawa, and M Itoh
March 1997, Gastroenterology,
M Sasakii, and T Joh, and Y Yokoyama, and K Seno, and K Tsuchida, and T Kurokawa, and M Itoh
April 2021, United European gastroenterology journal,
M Sasakii, and T Joh, and Y Yokoyama, and K Seno, and K Tsuchida, and T Kurokawa, and M Itoh
January 2015, Asian Pacific journal of cancer prevention : APJCP,
M Sasakii, and T Joh, and Y Yokoyama, and K Seno, and K Tsuchida, and T Kurokawa, and M Itoh
June 2002, The Journal of antimicrobial chemotherapy,
M Sasakii, and T Joh, and Y Yokoyama, and K Seno, and K Tsuchida, and T Kurokawa, and M Itoh
January 1999, The Yale journal of biology and medicine,
M Sasakii, and T Joh, and Y Yokoyama, and K Seno, and K Tsuchida, and T Kurokawa, and M Itoh
January 1998, Journal of clinical gastroenterology,
M Sasakii, and T Joh, and Y Yokoyama, and K Seno, and K Tsuchida, and T Kurokawa, and M Itoh
August 1993, The American journal of gastroenterology,
M Sasakii, and T Joh, and Y Yokoyama, and K Seno, and K Tsuchida, and T Kurokawa, and M Itoh
April 1986, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
M Sasakii, and T Joh, and Y Yokoyama, and K Seno, and K Tsuchida, and T Kurokawa, and M Itoh
January 2011, Chemotherapy,
Copied contents to your clipboard!